A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Capmatinib (Primary) ; Digoxin; Rosuvastatin
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis; Novartis Pharmaceuticals
- 26 May 2017 Status changed from active, no longer recruiting to completed.
- 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Jul 2016 Planned End Date changed from 1 May 2017 to 1 Sep 2017.